Latest ExAblate Stories
TIRAT CARMEL, Israel, March 19 /PRNewswire/ -- InSightec Ltd. reported today that it has closed an internal round of financing totaling US$15 million from its existing investors. Elbit Imaging Ltd. (NASDAQ: EMITF) ("EI") has invested US$7.5M on March 18, 2009. Additional US$7.5M would be invested no later than 12 months following the date hereof by its existing investors. The investment will take the form of Preferred Shares B, which are convertible to InSightec's ordinary...
CHICAGO, Feb. 24 /PRNewswire/ -- A project to create awareness among African American women about a non-invasive outpatient uterine fibroid treatment using high energy ultrasound will begin in the Chicago area in March, led by two prominent and well respected African American gynecologists, Dr. Leonard Lawson and Dr. Eric Brown. According to the U.S. Department of Health and Human Services, African American women are 2 to 3 times more likely to get uterine fibroids than women of other...
TIRAT CARMEL, Israel, December 16 /PRNewswire/ -- InSightec Ltd. announced today that cancer patients suffering pain caused by tumors that have spread to their bones have a new online resource for information about their condition. The website, http://www.MyCancerPain.org, provides background on bone metastases, as well as detailed information about a clinical trial being conducted at eleven centers in the U.S., Canada and Israel to evaluate whether treatment with the noninvasive,...
TIRAT CARMEL, Israel, December 2 /PRNewswire/ -- InSightec Ltd. announced today that new publications show that Magnetic Resonance-guided Focused Ultrasound (MRgFUS) with the ExAblate(R) system has the potential to be an effective noninvasive pain-relieving treatment for tumors that have spread to the bones (bone metastases). The results of a 31 patient study appear in the November 11 online issue of Annals of Surgical Oncology, while data from an eleven-patient subgroup analysis of...
CHARLOTTE, N.C., July 2 /PRNewswire/ -- USHIFU, LLC (USHIFU), the distributor and provider of non-invasive high intensity focused ultrasound for prostate cancer, announced today that it has completed the acquisition of Focus Surgery, Inc. (FSI) of Indianapolis, IN, the creator and manufacturer of the Sonablate(R) 500, an image-guided acoustic ablation device. This acquisition will accelerate USHIFU's ability to expand the FSI HIFU technology platform, as well as gain access to new markets,...
Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced the acceleration of patient enrollment relating to the United States Food and Drug Administration ("FDA") clinical trials for the Sonablate® 500 ("SB500"), a medical device using high intensity focused ultrasound ("HIFU") for non-invasive treatment of prostate cancer. The Sonablate® 500 is approved by the FDA as an...
ST. LOUIS, May 24 /PRNewswire/ -- One out of every three hysterectomies performed are due to benign tumors (uterine fibroids). Over 25 percent of women in the United States have clinically symptomatic uterine fibroids and as many as 77 percent of all women could have uterine fibroids and many do not even know it. There is good news for St. Louis women suffering from the painful, embarrassing side effects of uterine fibroids. Local area gynecologists now have access to a revolutionary...
LAS VEGAS, Jan. 11 /PRNewswire/ -- Las Vegas women suffering from the painful, embarrassing side effects of uterine fibroids now have local access to a revolutionary non-invasive outpatient procedure that combines magnetic resonance imaging and focused ultrasound to destroy these tumors. ExAblate of Las Vegas, the first Nevada facility to offer this incisionless procedure with the ExAblate 2000 system, is now open at 7170 Smoke Ranch Road, Suite A. "The ExAblate technology combines magnetic...
LONG ISLAND, N.Y., Jan. 11 /PRNewswire/ -- Metropolitan Area women suffering from the painful, embarrassing side effects of uterine fibroids now have local access to a revolutionary non-invasive outpatient procedure that combines magnetic resonance imaging and focused ultrasound to destroy these tumors. ExAblate of Long Island, the first Metropolitan Area facility to offer this incisionless procedure with the ExAblate 2000 system, is now open at 900 Northern Boulevard in Great Neck. "The...
By David Douglas NEW YORK (Reuters Health) - For women with fibroids, treatment with focused ultrasound guided by magnetic resonance imaging (MRI) seems to relieve symptoms well, researchers report. "This is the first large study using MR-guided focused ultrasound surgery for uterine fibroids and demonstrates successful symptom reduction at 6 and 12 months with a low rate of adverse events," lead investigator Dr. Elizabeth A. Stewart told Reuters Health. Stewart, of Brigham and...
